Efficacy and Safety of CART Cell Therapy in Aggressive B‐Cell Lymphomas Involving the Gastrointestinal Tract by Lixia Ma, Yimeng Dou, Rui Liu, Teng Xu, Fan Yang, Peihao Zheng, Shaomei Feng, Yuelu Guo, Hui Shi, Fei Xue, Biping Deng, Xiaoyan Ke, Kai Hu

“…Conclusion Generally, the CART cell therapy is valid in relapsed/refractory B‐cell lymphoma with gastrointestinal involvement, but gastrointestinal bleeding is a unique risk factor that requires special attention, particularly in patients with high gastrointestinal tumor burden, as it is associated with poor efficacy and survival.…”
Get full text

Aging impairs CD8 T cell responses in adoptive T-cell therapy against solid tumors by Gulfiya Kadyrzhanova, Miho Tamai, Shukla Sarkar, Rajkumar Singh Kalra, Hiroki Ishikawa

Subjects: Get full text

Targeting ferroptosis: opportunities and challenges of mesenchymal stem cell therapy for type 1 diabetes mellitus by Le Dai, Qing Wang

Get full text

Herpesvirus Infections After Chimeric Antigen Receptor T-Cell Therapy and Bispecific Antibodies: A Review by Joseph Sassine, Emily A. Siegrist, Roy F. Chemaly

Subjects: Get full text

Unleashing the potential of a low CpG Passer transposon for superior CAR-T cell therapy by Jianyao Zeng, Yan Sun, Yan Sun, Yuan Fang, Xiaodie Wang, Qian Huang, Pingjing Zhang, Meiqi Shao, Pei Wang, Jingbo Cheng, Meng Di, Tao Liu, Qijun Qian, Qijun Qian, Qijun Qian

“…Additionally, de novo DNA methylation programs promote T cell exhaustion, which poses a significant limitation for CAR-T cell therapy applications.MethodsHigh-throughput liquid protein chip and CBA analyses were utilized to determine the expression levels of inflammatory factors. …”
Get full text

Efficacy of Topical Mesenchymal Stem Cell Therapy in the Treatment of Experimental Dry Eye Syndrome Model by Emrullah Beyazyıldız, Ferda Alpaslan Pınarlı, Özlem Beyazyıldız, Emine Rümeysa Hekimoğlu, Uğur Acar, Muhammed Necati Demir, Aynur Albayrak, Figen Kaymaz, Güngör Sobacı, Tuncay Delibaşı

Get full text

Mesenchymal Stem Cell Therapy for Cardiac Inflammation: Immunomodulatory Properties and the Influence of Toll-Like Receptors by F. van den Akker, S. C. A. de Jager, J. P. G. Sluijter

Get full text

Cryo-thermal therapy reshaped the tumor immune microenvironment to enhance the efficacy of adoptive T cell therapy by Shicheng Wang, Peng Peng, Junjun Wang, Zelu Zhang, Ping Liu, Lisa X. Xu

Subjects: Get full text

Advancements and Future Directions of Dual-Target Chimeric Antigen Receptor T-Cell Therapy in Preclinical and Clinical Studies by Chenyun Zhang, Haizhou Liu

Get full text

Gut microbiota modulation in cardiac cell therapy with immunosuppression in a nonhuman primate ischemia/reperfusion model by Hung-Chih Chen, Yu-Che Cheng, Marvin L. Hsieh, Po-Ju Lin, Emily F. Wissel, Theodore Steward, Cindy M. C. Chang, Jennifer Coonen, Timothy A. Hacker, Timothy J. Kamp, Patrick C. H. Hsieh

“…Abstract Gut microbiota affect transplantation outcomes; however, the influence of immunosuppression and cell therapy on the gut microbiota in cardiovascular care remains unexplored. …”
Get full text

Mesenchymal Stem Cell Therapy for Acute Myocardial Infarction: Protocol for a Systematic Review and Meta-Analysis by Michael Vincent DiCaro, Brianna Yee, KaChon Lei, Kavita Batra, Buddhadeb Dawn

Get full text

Outcome of Allogeneic Adult Stem Cell Therapy in Dogs Suffering from Osteoarthritis and Other Joint Defects by Kiran Shah, Tara Drury, Ivelise Roic, Peter Hansen, Mark Malin, Richard Boyd, Huseyin Sumer, Ray Ferguson

Get full text

Autologous Stem Cell Therapy in Critical Limb Ischemia: A Meta-Analysis of Randomized Controlled Trials by Baocheng Xie, Houlong Luo, Yusheng Zhang, Qinghui Wang, Chenhui Zhou, Daohua Xu

“…Meta-analysis showed that cell therapy significantly increased the probability of ulcer healing (RR = 1.73, 95% CI = 1.45–2.06), angiogenesis (RR = 5.91, 95% CI = 2.49–14.02), and reduced the amputation rates (RR = 0.59, 95% CI = 0.46–0.76). …”
Get full text

Diabetes insipidus and Guillain-Barré-like syndrome following CAR-T cell therapy: a case report by Christian Koch, Patrick Roth, Juliane Fleischer, Todor Popov, Karl Frontzek, Bettina Schreiner, Markus G. Manz, Simone Unseld, Antonia M. S. Müller, Norman F. Russkamp

“…Background Immune effector cell-associated neurotoxicity syndrome (ICANS) is a common adverse event of CD19-directed chimeric antigen receptor (CAR) T cell therapy. Other neurological adverse events, however, have not methodically been described and studied. …”
Get full text

Impact of prior CAR T-cell therapy on mosunetuzumab efficacy in patients with relapsed or refractory B-cell lymphomas by Elise A. Chong, Elicia Penuel, Ellen B. Napier, Rachel K. Lundberg, Lihua E. Budde, Mazyar Shadman, Matthew J. Matasar, Nancy L. Bartlett, Ian W. Flinn, Francesc Bosch, Keith Fay, Andre Goy, Anita Kumar, Loretta J. Nastoupil, Michael C. Wei, Mei Wu, Shen Yin, Joseph A. Fraietta, Emeline R. Chong, Stephen J. Schuster

Get full text

Management of CAR-T cell therapy in patients with multiple myeloma: a systematic review and expert consensus in Australia by P. Joy Ho, Hang Quach, M. Hasib Sidiqi, M. Hasib Sidiqi, Cindy H. Lee, Jason Butler, Andrew Spencer, Kenneth Micklethwaite, Kenneth Micklethwaite, Kenneth Micklethwaite, Kenneth Micklethwaite, Jingya Li, Elissa Cusson, Robert Bagnall, Simon J. Harrison

Subjects: Get full text

Advances in Cell and Immune Therapies for Melanoma by Tanase Timis, Sanda Buruiana, Delia Dima, Madalina Nistor, Ximena Maria Muresan, Diana Cenariu, Adrian-Bogdan Tigu, Ciprian Tomuleasa

Subjects: Get full text

Efficient and Fast Differentiation of Human Neural Stem Cells from Human Embryonic Stem Cells for Cell Therapy by Xinxin Han, Liming Yu, Jie Ren, Min Wang, Zhongliang Liu, Xinyu Hu, Daiyu Hu, Yihong Chen, Li Chen, Ying Zhang, Yuehua Liu, Xiaoqing Zhang, Hua He, Zhengliang Gao

“…Optimized protocols for neural differentiation are necessary to produce functional human neural stem cells (hNSCs) for cell therapy. However, the qualified procedure is scarce and detailed features of hNSCs originated from hES cells are still unclear. …”
Get full text

CD19-directed chimeric antigen receptor T-cell therapy: what can we learn from the haematologist? by Marie José Kersten, Maria Theresa Kuipers

“…CD19-directed chimeric antigen receptor (CAR) T-cell therapy, originally developed for haematological malignancies, has recently emerged as a promising therapy for patients with autoimmune diseases. …”
Get full text

Allogeneic DNT cell therapy synergizes with T cells to promote anti-leukemic activities while suppressing GvHD by Jongbok Lee, Hyeonjeong Kang, Branson Chen, Yoosu Na, Ismat Khatri, Fraser Soares, Housheng Hansen He, Arjun D. Law, Tianzhong Pan, Armin Gerbitz, Xiaoyu Zhu, Mark D. Minden, Li Zhang

Get full text